Pharmicell (005690) - Total Assets
Based on the latest financial reports, Pharmicell (005690) holds total assets worth ₩130.02 Billion KRW (≈ $88.12 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Pharmicell (005690) shareholders funds for net asset value and shareholders' equity analysis.
Pharmicell - Total Assets Trend (2010–2024)
This chart illustrates how Pharmicell's total assets have evolved over time, based on quarterly financial data.
Pharmicell - Asset Composition Analysis
Current Asset Composition (December 2024)
Pharmicell's total assets of ₩130.02 Billion consist of 48.4% current assets and 51.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 8.3% |
| Accounts Receivable | ₩16.16 Billion | 16.3% |
| Inventory | ₩19.78 Billion | 19.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩58.81 Million | 0.1% |
| Goodwill | ₩5.54 Billion | 5.6% |
Asset Composition Trend (2010–2024)
This chart illustrates how Pharmicell's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 005690 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmicell's current assets represent 48.4% of total assets in 2024, a decrease from 54.8% in 2010.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 27.6% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is inventory at 19.9% of total assets.
Pharmicell Competitors by Total Assets
Key competitors of Pharmicell based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Pharmicell - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.82 | 9.01 | 6.60 |
| Quick Ratio | 8.10 | 4.44 | 5.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩70.03 Billion | ₩35.47 Billion | ₩36.43 Billion |
Pharmicell - Advanced Valuation Insights
This section examines the relationship between Pharmicell's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.94 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 7.3% |
| Total Assets | ₩99.26 Billion |
| Market Capitalization | $736.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pharmicell's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Pharmicell's assets grew by 7.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Pharmicell (2010–2024)
The table below shows the annual total assets of Pharmicell from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩99.26 Billion ≈ $67.27 Million |
+7.29% |
| 2023-12-31 | ₩92.52 Billion ≈ $62.70 Million |
-15.62% |
| 2022-12-31 | ₩109.65 Billion ≈ $74.31 Million |
+16.23% |
| 2021-12-31 | ₩94.33 Billion ≈ $63.93 Million |
+35.26% |
| 2020-12-31 | ₩69.74 Billion ≈ $47.26 Million |
+10.24% |
| 2019-12-31 | ₩63.27 Billion ≈ $42.87 Million |
+7.02% |
| 2018-12-31 | ₩59.12 Billion ≈ $40.06 Million |
-7.27% |
| 2017-12-31 | ₩63.75 Billion ≈ $43.20 Million |
-37.47% |
| 2016-12-31 | ₩101.95 Billion ≈ $69.09 Million |
+2.60% |
| 2013-12-31 | ₩99.37 Billion ≈ $67.34 Million |
-27.16% |
| 2012-12-31 | ₩136.43 Billion ≈ $92.45 Million |
+34.87% |
| 2011-12-31 | ₩101.15 Billion ≈ $68.55 Million |
+240.07% |
| 2010-12-31 | ₩29.74 Billion ≈ $20.16 Million |
-- |
About Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfuse… Read more